Partner Gabor Garai was quoted in an article that appeared in the Boston Globe on May 10, 2013 titled, “Markets draw life science start-ups.” The article discussed how rebounding financial markets are attracting an increasing number of life sciences start-ups looking to raise large amounts of money through IPOs — resulting in the anticipated biggest coming-out class for life sciences since 2007. The article highlighted the risks to going public, but noted that public offerings are emerging as the financing event of choice for start-ups that do not want to give up too much control to private investors or larger industry players. Mr. Garai was quoted as saying, “When it comes to drugs, the cost of getting anything to market has become inordinate. Right now, there’s more money in the public markets chasing deals than in the venture capital markets. We’re seeing the first signs of spring after a cold winter for IPOs.”
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"